gdc
PSSGuide_2021
Breast Cancer

Drugs for Breast Cancer

Here are the drugs and financial support services available to patients receiving treatment for Breast Cancer.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Celgene
800-931-8691

Abraxane is a microtubule inhibitor used for the treatment of patients with metastatic breast cancer after failure of combination chemotherapy or after disease relapse within 6 months of adjuvant chemotherapy.

Celgene offers 3 financial assistance programs for patients using Abraxane:

Celgene Commercial Co-pay Program

This program reduces the prescription copay for Abraxane to $0, for qualifying patients with private or commercial insurance, with up to $10,000 provided annually.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria, may be able to receive Abraxane for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and co-insurance.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of postmenopausal women with advanced HR-positive, HER2-negative breast cancer, in combination with Aromasin, after failure of treatment with Femara or Arimidex.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance may be responsible for $0 per month in copay and co-insurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Free Trial Program

Eligible patients can receive a 1-time per dose free 14-day supply of Afinitor for an FDA-approved indication. The supply will be shipped directly to the patient.

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Afinitor for free until prescription drug coverage becomes available to them.

Arimidex (anastrozole) Tablets

Drug company: ANI Pharmaceuticals
855-250-2483

Arimidex is an aromatase inhibitor used as a first-line treatment of postmenopausal women with HR-positive or unknown HR status, locally advanced or metastatic breast cancer. Arimidex is also used for adjuvant treatment of postmenopausal women with HR-positive early breast cancer, and as second-line treatment for postmenopausal women with advanced breast cancer that progressed after Nolvadex or Soltamox therapy.

ANI Pharmaceuticals offers 1 financial assistance program for patients who have been prescribed Arimidex:

Arimidex Patient Direct Program

Patients with a valid prescription for Arimidex, regardless of insurance, are eligible to receive Arimidex at a cost of $60 for 30 tablets or $180 for 90 tablets. Prescription orders for patients with Medicare Part D coverage will be processed without the use of insurance and cannot be applied to the patient’s out-of-pocket costs. Patients should enroll in the program online, and their prescription of Arimidex will be shipped directly to their home within 7 to 10 business days.

Aromasin (exemestane) Tablets

Drug company: Pfizer
844-989-7284

Aromasin is an aromatase inhibitor used as an adjuvant treatment of postmenopausal women with ER-positive early breast cancer who have received 2 to 3 years of Nolvadex or Soltamox therapy before being switched to Aromasin for completion of a total of 5 consecutive years of adjuvant hormone therapy, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed after Nolvadex or Soltamox therapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Aromasin:

Aromasin Savings Card

Patients with commercial insurance who meet the Aromasin Savings Card program requirements may pay as little as $4 for a prescription, for a maximum savings of $300 for a 30-day fill and an annual maximum savings of $3,600. The Aromasin Savings Card may be requested by completing a form online (at www.aromasin.com/savings) or by calling 866-562-6151.

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Aromasin, and meet certain income limits but do not have sufficient prescription coverage to pay for the medicine can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Ellence (epirubicin hydrochloride injection)

Drug company: Pfizer
844-989-7284

Ellence is an anthracycline topoisomerase II inhibitor used as a component of adjuvant therapy in patients with axillary node tumor after resection of primary breast cancer.

Pfizer Oncology Together offers 1 financial assistance program for patients using Ellence:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Ellence, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Enhertu (fam-trastuzumab) Injection

Drug company: Daiichi Sankyo/AstraZeneca
833-364-3788

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adults with unresectable or metastatic HER2-positive breast cancer after at least 2 previous anti-HER2 regimens in the metastatic setting.

Daiichi Sankyo and AstraZeneca offer 2 patient assistance programs for patients who have been prescribed Enhertu:

Enhertu Patient Savings Program

Eligible patients who have commercial insurance may pay as little as $0 per prescription of Enhertu, with a maximum benefit of up to $26,000 per year, to help with out-of-pocket costs. This program has no income requirements.

Enhertu Patient Assistance Program

Patients who are uninsured, underinsured, or who have Medicare, and who meet the income eligibility requirements, may receive Enhertu for free. Medicare beneficiaries must not be eligible for or enrolled in low income subsidy for Medicare Part D, and must have spent at least 3% of their annual household income on prescription medicines in the current year.

Fareston (toremifene citrate) Tablets

Drug company: Kyowa Kirin
800-676-5884

Fareston is an estrogen agonist/antagonist used for the treatment of metastatic breast cancer in postmenopausal women with ER-positive or unknown tumors.

Kyowa Kirin, through Patient Rx Solutions, offers 2 financial assistance programs for patients using Fareston:

Fareston Copay Assistance Card Program

Insured patients can use the Fareston Copay Assistance Card once monthly. With the card, patients will pay the initial $20 of their copay, and any remaining out-of-pocket costs will be reduced by up to $150 monthly.

Fareston Patient Assistance Program

Patients who do not have insurance and who do have an income of 300% or less of the current federal poverty level are eligible to receive free Fareston tablets.

Faslodex (fulvestrant)

Drug company: AstraZeneca
844-275-2360

Faslodex is an estrogen receptor antagonist used for firstline treatment of HR-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy, and for HR-positive metastatic breast cancer in postmenopausal women with disease progression after anti-estrogen therapy. Faslodex is also used for HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio, in women whose disease progressed after endocrine therapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Faslodex:

FASLODEX Co-pay Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per dose of Faslodex, with a maximum savings of $6,000 yearly. Eligible patients must have private health insurance that partially covers medication costs for Faslodex.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in limited income subsidy for Medicare Part D, and/or a life-changing event in the past year that impacted finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used in combination with Abraxane for the first-line treatment of patients with metastatic breast cancer, after failure of anthracycline-containing adjuvant chemotherapy, unless anthracyclines were contraindicated.

Lilly Oncology does not currently have any specific financial assistance program for Gemzar.

Halaven (eribulin mesylate)

Drug company: Eisai
866-613-4724

Halaven is a microtubule inhibitor used to treat metastatic breast cancer in patients who received at least 2 chemotherapy regimens with an anthracycline and a taxane.

Eisai offers 2 financial assistance programs for patients using Halaven:

Halaven $0 Co-Pay Program

This program assists patients with private insurance so that the copay for Halaven will be no more than $0, with a limit of $18,000 yearly.

Halaven Patient Assistance Program

This program provides Halaven at no cost to financially challenged patients who meet program eligibility criteria.

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Herceptin is an HER2 receptor antagonist used for the treatment of patients with HER2-overexpressed breast cancer.

Genentech Oncology offers 2 financial assistance programs for patients using Herceptin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Herceptin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Herceptin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection

Drug company: Genentech
866-422-2377

Herceptin Hylecta is a combination of the monoclonal antibody Herceptin (trastuzumab), an HER2 antagonist, and recombinant human hyaluronidase, an endoglycosidase, used for the adjuvant treatment of patients with HER2-positive, node-positive or node-negative breast cancer, in combination with chemotherapy, or alone in patients who received multiple anthracycline-based therapies. Herceptin Hylecta is also used in patients with HER2-positive metastatic breast cancer who received 1 or more chemotherapy regimens for metastatic disease.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Herceptin Hylecta:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Herceptin Hylecta, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Herceptin Hylecta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Ibrance (palbociclib) Capsules/Tablets

Drug company: Pfizer
877-744-5675

Ibrance is a kinase inhibitor used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor, as initial endocrine-based therapy in postmenopausal women or in men, and in combination with fulvestrant, in adults whose disease progressed after endocrine therapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Ibrance:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists privately insured patients so that their copay for Ibrance is $0 monthly, with a maximum savings benefit of $25,000 yearly.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Ibrance for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Ibrance for free.

Ixempra (ixabepilone)

Drug company: R-Pharm US
855-991-7277

Ixempra is a microtubule inhibitor used, in combination with Xeloda, for the treatment of patients with locally advanced or metastatic breast cancer after failure of an anthracycline and a taxane, and as monotherapy for the treatment of locally advanced or metastatic breast cancer in patients after failure of an anthracycline, a taxane, and Xeloda treatment.

R-Pharm US offers 1 financial assistance program for patients using Ixempra:

R-Pharm US Access + Support Program

This program offers financial assistance for Ixempra, including a copay program assisting with out-of-pocket copay or co-insurance requirements for eligible, privately insured patients. A patient assistance program is also available for eligible, uninsured patients.

Kadcyla (ado-trastuzumab emtansine)

Drug company: Genentech
866-422-2377

Kadcyla is an HER2-targeted antibody and microtubule inhibitor conjugate used for the treatment of patients with HER2-positive metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination. Patients should have either received previous therapy for metastatic disease, or had disease recurrence during or within 6 months of completing adjuvant therapy. Kadcyla is also used for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Kadcyla:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Kadcyla, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Kadcyla free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Kanjinti (trastuzumab-anns)

Drug company: Amgen
888-427-7478

Kanjinti, a biosimilar to Herceptin, is an HER2 receptor antagonist used for the treatment of patients with HER2-positive breast cancer.

Amgen offers 2 financial assistance programs for patients who have been prescribed Kanjinti:

Amgen FIRST STEP Program

With this program, eligible patients who have private insurance will pay $0 for the first dose of Kanjinti and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Kanjinti for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used, in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer expressing PD-L1, as determined by an FDA-approved test.

Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Kisqali (ribociclib) Tablets

Drug company: Novartis
800-282-7630

Kisqali is a kinase inhibitor used, in combination with an aromatase inhibitor, as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. Kisqali is also used, in combination with Faslodex, for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression with endocrine therapy.

Novartis’ Patient Assistance NOW Oncology offers 4 financial assistance programs for patients using Kisqali:

Kisqali Free Treatment Voucher

Patients who have a valid prescription for Kisqali are eligible to receive 1 free treatment cycle of Kisqali, with a maximum of 63 tablets.

Kisqali 5-Treatment Cycle Access Program

Patients with private insurance who are experiencing a delay in insurance coverage can take advantage of this program, which will provide up to 5 treatment cycles of Kisqali.

Novartis Oncology Universal Co-Pay Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $0 per month for Kisqali. Novartis pays the remaining balance until an annual maximum of $15,000 is met.

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Kisqali for free until prescription drug coverage becomes available to them.

Lynparza (olaparib) Capsules/Tablets

Drug company: AstraZeneca
Phone: 800-292-6363

Lynparza is a PARP inhibitor used for the treatment of patients with HER2-negative metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutation after receiving chemotherapy in the adjuvant, neoadjuvant, or metastatic setting.

AstraZeneca offers 2 financial assistance programs for patients using Lynparza:

Lynparza Co-pay Savings Program

Although the patient’s out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per month for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must have an annual household income of $100,000 or less and spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare limited income subsidy. Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Nerlynx (neratinib) Tablets

Drug company: Puma Biotechnology
844-276-5153

Nerlynx is a kinase inhibitor used for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed or -amplified breast cancer, after adjuvant therapy with Herceptin. Nerlynx is also used, in combination with Xeloda, for the treatment of adults with advanced or metastatic HER2-positive breast cancer who have received 2 or more anti-HER2 regimens in the metastatic setting.

Puma Biotechnology offers 3 financial assistance programs for patients using Nerlynx:

Puma Patient Lynx Co-Pay Savings Program

Eligible patients with private insurance may pay as little as $10 per prescription of Nerlynx and will be enrolled in this program through a specialty pharmacy.

Nerlynx Patient Assistance Program

Nerlynx is provided at no cost to patients who are uninsured and meet certain financial qualifications.

Nerlynx Quick Start Program

Eligible patients who are experiencing delayed access to Nerlynx may be eligible to receive for free a 3-week supply of Nerlynx.

Ogivri (trastuzumab-dkst) Injection

Drug company: Mylan
833-695-2623

Ogivri, biosimilar to Herceptin, is an HER2 receptor antagonist used for the treatment of patients with HER2-positive breast cancer.

Mylan offers 2 financial assistance programs for patients who have been prescribed Ogivri:

Mylan Advocate Co-Pay Assistance Program

This program pays the full out-of-pocket expense of Ogivri for eligible, privately insured patients.

Mylan Advocate Patient Assistance

Uninsured patients who cannot afford their medication may be eligible to receive Ogivri free of charge. Eligibility requirements include residency, income, and other factors.

Ontruzant (trastuzumab-dttb) for Injection

Drug company: Merck
855-257-3932

Ontruzant, a biosimilar to Herceptin, is used, in combination with paclitaxel, for the first-line treatment of patients with HER2-overexpressing metastatic breast cancer. Ontruzant is also used alone for the treatment of patients with HER2-overexpressing breast cancer who have received 1 or more chemotherapy regimens for metastatic breast cancer.

Merck offers 2 financial assistance programs for patients who have been prescribed Ontruzant:

Merck Co-pay Assistance Program

Eligible patients who have private insurance will pay the first $5 of their copay per infusion of Ontruzant, with a maximum benefit of $25,000 per patient per year.

Merck Patient Assistance Program

Patients who do not have insurance, or who cannot afford Ontruzant even with prescription drug coverage, may be eligible for free drug product from the Merck Patient Assistance Program if they meet certain financial, medical, and/or insurance criteria.

Perjeta (pertuzumab)

Drug company: Genentech
866-422-2377

Perjeta is an HER2 receptor antagonist used in combination with Herceptin and Taxotere for treatment of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease. Perjeta is also used in combination with Herceptin and Taxotere as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer.

Genentech Oncology offers 2 financial assistance programs for patients using Perjeta:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Perjeta, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Perjeta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection

Drug company: Genentech
866-422-2377

Phesgo is a combination of pertuzumab and trastuzumab, 2 HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, used for the neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer. Phesgo is also used for the adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence, and for the treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease.

Genentech Oncology offers 2 financial support programs for patients who have been prescribed Phesgo:

Genentech Oncology Co-pay Assistance Program

Eligible patients who have private insurance will pay just a $5 copay per prescription or infusion of Phesgo, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Phesgo free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Piqray (alpelisib) Tablets

Drug company: Novartis
800-282-7630

Piqray is a kinase inhibitor used, in combination with fulvestrant, for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer and a PIK3CA mutation, in patients whose disease progressed during or after endocrine therapy.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients who have been prescribed Piqray:

Novartis Oncology Universal Co-pay Program

Eligible patients with private insurance may pay as little as $0 monthly for Piqray. Novartis pays the remaining copay balance until a yearly maximum of $15,000 is met.

Free Trial Program and Access Program

Eligible patients receive a free supply of Piqray shipped directly to home or to another convenient location.

Novartis Patient Assistance Foundation

Uninsured or underinsured patients may receive financial assistance through this program. The patient must be a US citizen and provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Piqray for free until prescription drug coverage becomes available to them.

Talzenna (talazoparib)

Drug company: Pfizer
877-744-5675

Talzenna is a PARP inhibitor used for the treatment of adults with HER2-negative locally advanced or metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutations, as identified by an FDA-approved test called BRACAnalysis CDx.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Talzenna:

Pfizer Oncology Together Co-Pay Savings Card

Eligible patients who have private insurance may pay as little as $0 per month for Talzenna, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who have no health insurance may qualify to receive Talzenna for free or at a savings. Eligible patients with government insurance may receive Talzenna for free if they cannot find independent charitable foundation support.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used, in combination with Abraxane, for the treatment of patients with unresectable, locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDAapproved test.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Tecentriq:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Trazimera (trastuzumab-qyyp)

Drug company: Pfizer
877-744-5675

Trazimera is a HER2/neu receptor antagonist and a biosimilar to Herceptin, used for adjuvant treatment of patients with HER2-overexpressing node-positive or node-negative breast cancer, in combination with various chemotherapy regimens, or as a single therapy after anthracycline-based therapy. Trazimera is also used for first-line treatment, in combination with paclitaxel, of patients with HER2-overexpressing metastatic breast cancer, and as a single therapy in patients who have received 1 or more chemotherapy regimens for metastatic disease.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Trazimera:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Trazimera is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Trazimera for free or at a savings. Eligible patients with government insurance may also receive Trazimera for free if they cannot find independent charitable foundation support.

Trodelvy (sacituzumab govitecan-hziy) Injection

Drug company: Immunomedics
844-876-3358

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adults with metastatic triple-negative breast cancer who have received at least 2 previous therapies for metastatic disease.

Immunomedics offers 2 financial assistance programs for patients who have been prescribed Trodelvy:

Trodelvy Savings Program

Eligible patients who have commercial or private insurance may pay $0 out-of-pocket for Trodelvy, with a maximum benefit of $25,000 per year.

Immunomedics Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Trodelvy free of charge.

Tukysa (tucatinib) Tablets

Drug company: Seagen
855-473-2873

Tukysa is a kinase inhibitor used, in combination with trastuzumab and capecitabine, for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more previous HER2-directed regimens for metastatic disease.

Seagen Secure offers 2 financial assistance programs for patients who have been prescribed Tukysa:

Commercial Out-of-Pocket Assistance Program

Patients who have commercial or private insurance who meet the program eligibility requirements may pay as little as $5 per prescription fill of Tukysa.

Patient Assistance Program

Eligible patients who have no insurance and who meet the program income requirements may receive Tukysa for free for up to 1 year.

Tykerb (lapatinib) Tablets

Drug company: Novartis
800-245-5356

Tykerb is a kinase inhibitor used in combination with Xeloda for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and Herceptin. Tykerb can also be used in combination with Femara for the treatment of postmenopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tykerb:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance for Tykerb. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

For patients without insurance to be eligible for financial assistance through this program, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Tykerb for free until prescription drug coverage becomes available to them.

Verzenio (abemaciclib) Tablets

Drug company: Eli Lilly
844-837-9364

Verzenio is a kinase inhibitor used, in combination with Faslodex, for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed after endocrine therapy, and as monotherapy for patients with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed after endocrine therapy and before chemotherapy in the metastatic setting. Verzenio is also used, in combination with an aromatase inhibitor, as initial endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

Lilly Oncology offers 2 financial assistance programs for patients who have been prescribed Verzenio:

Verzenio Continuous Care Program

This personalized care program offers the patient individual help to identify financial savings opportunities for patients taking Verzenio, navigate through the insurance process related to Verzenio, and answer any questions patients may have about the drug.

Verzenio Savings Card

Eligible patients with private insurance will receive the first 3 months of Verzenio at no cost, and then pay as little as $0 per month for their prescription, with a maximum annual savings of $25,000.

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Xeloda is a nucleoside metabolic inhibitor with antineoplastic activity used in combination with Taxotere after failure of anthracycline-containing therapy to treat patients with metastatic breast cancer. Xeloda can also be used alone in patients with disease resistant to Abraxane and to an anthracycline-containing regimen.

Genentech Oncology offers 1 financial support assistance program for patients who have been prescribed Xeloda:

Genentech Patient Foundation

This foundation provides Xeloda free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Zoladex (goserelin acetate implant)

Drug company: TerSera Therapeutics
855-686-8725

Zoladex is a gonadotropin-releasing hormone agonist used, in combination with flutamide, for the palliative treatment of premenopausal or perimenopausal women with advanced breast cancer.

TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Zoladex:

Zoladex Copay Card

Eligible patients with private insurance may pay as little as $0 for their prescription of Zoladex, with a maximum benefit of $2,000 per year. Eligible patients who are paying cash and whose prescriptions are not paid by any government programs will receive up to $300 off each 1-month supply of Zoladex.

Zoladex Patient Assistance Program

For eligible patients who do not have commercial insurance, this program may provide free Zoladex for up to 1 year before renewal is required. The medicine is sent in a 90-day supply to the patient’s home or doctor’s office.

Table. Drugs Prescribed for Breast Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Arimidex (anastrozole) Tablets
  • Drug company
  • ANI Pharmaceuticals
  • Indications
  • Postmenopausal, HR-positive early breast cancer

    First-line treatment of postmenopausal HR-positive or HR-unknown, locally advanced or metastatic breast cancer

    Second-line treatment of postmenopausal advanced breast cancer after Nolvadex or Soltamox therapy
  • Patient support services
  • Arimidex Patient Direct Program
    855-250-2483

    Drug name (generic name)
  • Aromasin (exemestane) Tablets
  • Drug company
  • Pfizer
  • Indications
  • Postmenopausal ER-positive early breast cancer

    Postmenopausal advanced breast cancer, after Nolvadex or Soltamox therapy
  • Patient support services
  • Aromasin Savings Card
    866-562-6151

    Pfizer Patient Assistance Program
    844-989-7284

    Drug name (generic name)
  • Ellence (epirubicin hydrochloride injection)
  • Drug company
  • Pfizer
  • Indications
  • Axillary node tumor after resection of primary breast cancer
  • Patient support services
  • Pfizer Patient Assistance Program
    844-989-7284

    Drug name (generic name)
  • Enhertu (fam-trastuzumab) Injection
  • Drug company
  • Daiichi Sankyo and AstraZeneca
  • Indications
  • Treatment of adults with unresectable or metastatic HER2-positive breast cancer, after at least 2 previous HER2-directed regimens for metastatic disease
  • Patient support services
  • Enhertu Patient Savings Program
    833-364-3788

    Enhertu Patient Assistance Program
    833-364-3788


    Drug name (generic name)
  • Faslodex (fulvestrant)
  • Drug company
  • AstraZeneca
  • Indication
  • First-line treatment of HR-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy

    HR-positive metastatic breast cancer in postmenopausal women, after anti-estrogen therapy

    HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio
  • Patient support services
  • FASLODEX Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    844-275-2360

    Drug name (generic name)
  • Gemzar (gemcitabine)
  • Drug company
  • Eli Lilly
  • Indication
  • Metastatic breast cancer, in combination with Abraxane
  • Patient support services
  • (No specific program)
    866-472-8663


    Drug name (generic name)
  • Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection
  • Drug company
  • Genentech
  • Indications
  • Adjuvant treatment of HER2-positive breast cancer, in combination with chemotherapy, or alone after multiple anthracycline-based therapies

    Treatment of HER2-positive metastatic breast cancer, after 1 or more chemotherapies for metastatic disease
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Ibrance (palbociclib) Capsules/Tablets
  • Drug company
  • Pfizer
  • Indications
  • Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, in postmenopausal women or in men

    Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, in adults whose disease progressed after endocrine therapy
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Ixempra (ixabepilone)
  • Drug company
  • R-Pharm US
  • Indications
  • Metastatic or locally advanced breast cancer, in combination with Xeloda

    Metastatic or locally advanced breast cancer, after failure of an anthracycline, a taxane, and Xeloda
  • Patient support services
  • R-Pharm US Access + Support Program
    855-991-7277

    Drug name (generic name)
  • Kadcyla (ado-trastuzumab emtansine)
  • Drug company
  • Genentech
  • Indication
  • HER2-positive metastatic breast cancer, after Herceptin and/or a taxane

    Adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease, after neoadjuvant taxane and trastuzumab-based treatment
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • Treatment, in combination with chemotherapy, of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400


    Drug name (generic name)
  • Lynparza (olaparib) Capsules/Tablets
  • Drug company
  • AstraZeneca
  • Indications
  • Treatment of deleterious or suspected deleterious germline BRCA mutation-positive, HER2-negative metastatic breast cancer, after chemotherapy
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363



    Drug name (generic name)
  • Ontruzant (trastuzumab-dttb) for Injection
  • Drug company
  • Merck
  • Indications
  • First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer

    Treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Perjeta (pertuzumab)
  • Drug company
  • Genentech
  • Indications
  • HER2-positive metastatic breast cancer, in combination with Herceptin and Taxotere

    Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, in combination with Herceptin and Taxotere
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection
  • Drug company
  • Genentech
  • Indications
  • Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer

    Adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence

    Treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331



    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indications
  • Treatment, in combination with Abraxane, of unresectable, locally advanced or metastatic triple-negative breast cancer expressing PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Trazimera (trastuzumab-qyyp)
  • Drug company
  • Pfizer
  • Indications
  • Adjuvant treatment, in combination with various chemotherapy regimens, of patients with HER2-overexpressing nodepositive or node-negative breast cancer

    Treatment of HER2-overexpressing breast cancer as a single agent, after anthracycline-based therapy

    First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer

    Treatment of HER2-overexpressing metastatic breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Trodelvy (sacituzumab govitecan-hziy) Injection
  • Drug company
  • Immunomedics
  • Indications
  • Treatment of adults with metastatic triple-negative breast cancer who have received at least 2 previous therapies for metastatic disease
  • Patient support services
  • Trodelvy Savings Program
    844-876-3358

    Immunomedics Patient Assistance Program
    844-876-3358

    Drug name (generic name)
  • Tukysa (tucatinib) Tablets
  • Drug company
  • Seagen
  • Indications
  • Treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more previous anti-HER2 regimens for metastatic disease
  • Patient support services
  • Commercial Out-of-Pocket Assistance Program
    855-473-2873

    Patient Assistance Program
    855-473-2873

    Drug name (generic name)
  • Tykerb (lapatinib) Tablets
  • Drug company
  • Novartis
  • Indications
  • Advanced or metastatic breast cancer overexpressing HER2, in combination with Xeloda, after an anthracycline, a taxane, and Herceptin

    Postmenopausal, HR-positive metastatic breast cancer overexpressing HER2, in combination with Femara
  • Patient support services
  • Novartis Oncology Universal Co-Pay Program
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Verzenio (abemaciclib) Tablets
  • Drug company
  • Eli Lilly
  • Indication
  • HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, in combination with Faslodex

    HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy and before chemotherapy in the metastatic setting, as monotherapy

    HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor
  • Patient support services
  • Verzenio Continuous Care Program
    844-837-9364

    Verzenio Savings Card
    844-837-9364

    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indications
  • Metastatic breast cancer, in combination with Taxotere, after failure of anthracycline-containing therapy
  • Patient support services
  • Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Zoladex (goserelin acetate implant)
  • Drug company
  • TerSera Therapeutics
  • Indication
  • Palliative treatment, in combination with flutamide, of premenopausal or perimenopausal women with advanced breast cancer
  • Patient support services
  • Zoladex Copay Card
    844-864-3014

    Zoladex Patient Assistance Program
    844-864-3014

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country